FIG 3.

Response rates in patients whose therapy changed after Molecular Tumor Board stratified by MS reflecting degree of matching (see Methods; n = 111 patients [two patients were excluded from the analysis, given SD ongoing at < 6 months of follow-up]) Patients who had MSs ≥ 40% (n = 26) were more likely to have favorable clinical response than patients who had MSs < 40% (n = 85): ORR is defined as CR or PR (P = .001). Clinical benefit rate includes SD for ≥ 6 months, PR, and CR (P < .001). See also Table 3. Because of rounding, numbers do not add to 100% in cohort with MS < 40%. CR, complete response; MS, matching score; ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable disease. Molecular Tumor Board–guided matched therapy correlated with improved breast and gynecologic cancer outcomes